肿瘤委员会与癌症治疗的影响联系不大

根据12月28日发表在《癌症杂志》上的一项研究，多学科肿瘤委员会与使用、质量或存活的衡量指标之间几乎没有联系，仅衡量肿瘤委员会的存在可能不足以确定它们对癌症治疗的影响国家癌症研究所杂志．

肿瘤委员会评论提供A.多学科方法治疗规划，包括来自许多专业的医生审查和讨论病症和患者的治疗。即使使用肿瘤板是普遍的，那么关于它如何影响的数据很少癌症护理．

为了确定肿瘤板的效果癌症care, Nancy L. Keating, M.D., M.P.H., Department of Health Care Policy, Harvard Medical School, and colleagues gathered information about tumor boards from 138 Veterans Affairs (VA) medical centers and linked cancer registry and administrative data to gauge receipt of stage-specific recommended care, survival, or use for patients with colorectal, lung, prostate, hematologic, and breast cancers diagnosed during 2001-2004 and followed through to 2005.

研究人员只发现肿瘤板的存在和接受患者的治疗类型之间的适度关联。肺，前列腺，血液学和乳腺癌的大多数类型的护理不受肿瘤板的存在或类型的影响。对于七项措施，某些类型的护理率较高（肺癌和前列腺癌)，而其他的(淋巴瘤和姑息治疗)较低。作者写道:“这可能意味着肿瘤板实际上并没有影响VA环境下癌症治疗的质量。”“需要更多的研究来了解肿瘤板的结构和格式，从而获得最高质量的治疗。”

In an accompanying editorial, Douglas W. Blayney, M.D., Stanford Cancer Institute, Stanford School of Medicine, notes that tumor boards may not influence quality in a large, integrated health system such as the VA as much as they might in smaller centers and writes that measures of adherence and survival are difficult to track and therefore while it is tough to determine the overall efficacy of tumor boards, they "have too long a history for them to be easily abandoned," adding that, "until there is carefully constructed public reporting of process adherence and outcome, we are left to hope that cancer doctors, their leaders, and the systems that they build will use recognized measures of structure and process and work toward superior outcomes."

---

---